LAS VEGAS—Correction of anemia with erythropoiesis-stimulated agents (ESAs) improves fatigue in dialysis patients compared with no treatment, researchers reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Oral iron is the optimal first treatment strategy for most iron-deficient, anemic chronic kidney disease (CKD) patients not yet on dialysis, based on a recent analysis presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—A novel interactive Web-based phosphorus education tool may help to improve phosphorus control in dialysis patients, according to a report at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Modifiable cardiovascular (CV) risk factors remain undertreated in a very high-risk population of patients with chronic kidney disease (CKD), new findings presented at the National Kidney Foundation’s Spring Clinical Meetings suggest.
LAS VEGAS—Sodium thiosulfate may hold promise as a treatment for calciphylaxis in patients with end-stage renal disease (ESRD), researchers reported here at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Obesity, current smoking, and diet are modifiable risk factors for developing chronic kidney disease (CKD), according to study findings presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—A novel multivitamin antioxidant nutraceutical may be useful in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to data reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Monthly requirements of erythropoiesis-stimulating agents (ESAs) to maintain target hemoglobin levels may be lower with larger doses of maintenance iron, according to data presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Albumunuria, proteinuria, lower estimated glomerular filtration rate (eGFR) in patients with diabetic nephropathy are significantly associated with hyperphosphatemia and anemia, researchers reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Bisphosphonate treatment in women with non-dialysis dependent chronic kidney disease (NDD-CKD) is associated with a decreased risk of death, but not of cardiovascular events, according to data presented at the National Kidney Foundation’s Spring Clinical Meetings.
Please login or register first to view this content.
